About

Neurobit – Unlocking Sleep Biomarkers for the Future of Medicine

Neurobit is an AI-powered health analytics company pioneering the use of sleep biomarkers to transform diagnostics, prediction, and therapy across cardiopulmonary, neurological, and mental health disorders. Led by Kishan, CEO of Neurobit, the company is building the foundation for a new era of personalized, predictive, and preventive healthcare.

Sleep has long been recognized as a powerful lens into human physiology, but its full potential has remained untapped due to the complexity and inefficiency of analyzing sleep studies. Polysomnography (PSG), the gold standard test for diagnosing sleep disorders such as sleep apnea, is a labor-intensive process requiring over an hour of manual scoring by trained technicians. This creates bottlenecks, delays in diagnosis, and higher costs for patients and healthcare systems.

Neurobit’s flagship solution, Neurobit PSG, is a breakthrough in this field. By leveraging advanced artificial intelligence, the platform reduces PSG scoring time from more than 4,000 seconds to just 40 seconds. This dramatic acceleration enables sleep clinics, hospitals, and diagnostic centers to improve throughput, reduce patient wait times, optimize reimbursement codes, and enhance overall efficiency without compromising accuracy.

The company’s technology extends beyond automation. By extracting and analyzing sleep biomarkers—derived from neural activity, heart rhythms, and respiratory patterns—Neurobit provides clinicians and researchers with actionable insights into broader health conditions. These biomarkers can serve as early indicators for cardiovascular risk, pulmonary diseases, neurodegenerative disorders, and mental health challenges, unlocking opportunities for earlier intervention and more tailored treatments.

Neurobit’s global adoption highlights its impact. Its platforms are used by more than 150 hospitals, universities, and research centers worldwide, spanning the United States, Europe, and Asia. The company’s research suite, the Neurobit Hub, supports clinical trials and translational research by offering over 40 validated biomarkers and enabling custom biomarker development. This makes it an invaluable tool for pharmaceutical companies, CROs, and academic institutions working on drug development, disease characterization, and digital endpoint discovery.

At the core of Neurobit’s offering are two integrated product lines:

Neurobit Score: a clinical suite that streamlines diagnostics, accelerates reporting, and integrates seamlessly into hospital workflows.

Neurobit Discover: a research and pharmaceutical suite that provides customizable biomarker analytics, enabling discovery of novel endpoints and powering precision-driven trials.

Together, these platforms allow Neurobit to bridge the worlds of clinical care and scientific research, serving both immediate patient needs and long-term medical innovation.

Looking ahead, Neurobit’s ambitions go far beyond sleep medicine. The company is targeting the $15 billion software-as-a-medical-device (SaMD) market, which is expanding at a 37% CAGR. By developing next-generation biomarkers such as NBT T1N Alpha for advanced disease profiling, Neurobit is expanding into cardiology, neurology, psychiatry, and respiratory medicine. Its modular platform design allows for rapid integration of new biomarkers, ensuring scalability across a wide range of clinical applications.

The company is also building a biomarker marketplace—a platform designed to connect hospitals, CROs, and pharmaceutical companies with validated digital endpoints. This marketplace will accelerate the adoption of biomarker-driven healthcare, drive collaboration across industries, and create new standards for precision medicine globally.

Neurobit operates with a strong focus on regulatory and clinical rigor. Its solutions are designed to comply with both FDA and MDR frameworks, and the company has completed validation studies in the United States and Asia to ensure safety, reliability, and trust. By embedding compliance into its design philosophy, Neurobit is well-positioned to scale globally across regulated healthcare environments.


By unlocking the untapped potential of sleep as a biomarker, Neurobit is not only revolutionizing diagnostics today but also shaping the future of predictive and preventive healthcare. With its advanced AI platform, expanding product ecosystem, and growing international adoption, the company is establishing itself as a leader in digital biomarkers—setting new standards for how medicine is delivered, discovered, and personalized.